



# Resource impact statement

Resource impact

Published: 26 May 2021

[www.nice.org.uk](http://www.nice.org.uk)

## No resource impact is anticipated

NICE has recommended trastuzumab deruxtecan for use within the Cancer Drugs Fund as an option for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

Trastuzumab deruxtecan will be available to the NHS in line with the [managed access agreement](#) with NHS England. As part of this, NHS England and Daiichi Sankyo have a commercial access agreement that makes trastuzumab deruxtecan available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

It is estimated that around 350 people per year with HER2-positive unresectable or metastatic breast cancer who have had 2 or more anti-HER2 therapies are eligible for treatment with trastuzumab deruxtecan.

The resource impact of trastuzumab deruxtecan will be covered by the Cancer Drugs Fund budget. More evidence on trastuzumab deruxtecan is being collected until the final results of the DESTINY-Breast01 and DESTINY-Breast02 trials are available. Once enough evidence is available, the process for exiting the Cancer Drugs Fund will begin and the review of the NICE guidance will start.

It will be available through the Cancer Drugs Fund until then. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in [NHS England's Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.